Professor Dive added: «We propose that this drug will be most useful in this
subset of patients who have elevated MCT1 levels and
need more effective treatments.
«There might be a
subset of COPD
patients who might benefit from statin use who don't
need a statin for cardiovascular reasons, but the heart and lungs are intertwined, and it's hard to tease out someone with COPD who doesn't have risk factors for cardiovascular disease,» Horovitz said.